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Abstract
We identified a key oncogenic pathway underlying neuroblastoma progression: specifically, MYCN, expressed at elevated
level, transactivates the miRNA 17-5p-92 cluster, which inhibits p21 and BIM translation by interaction with their mRNA 39
UTRs. Overexpression of miRNA 17-5p-92 cluster in MYCN-not-amplified neuroblastoma cells strongly augments their in vitro
and in vivo tumorigenesis. In vitro or in vivo treatment with antagomir-17-5p abolishes the growth of MYCN-amplified and
therapy-resistant neuroblastoma through p21 and BIM upmodulation, leading to cell cycling blockade and activation of
apoptosis, respectively. In primary neuroblastoma, the majority of cases show a rise of miR-17-5p level leading to p21
downmodulation, which is particularly severe in patients with MYCN amplification and poor prognosis. Altogether, our
studies demonstrate for the first time that antagomir treatment can abolish tumor growth in vivo, specifically in therapy-
resistant neuroblastoma.
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Introduction
MicroRNAs (miRNAs or miRs) are conserved ,22 nucleotide
non-coding RNAs: they repress protein expression at post-
transcriptional level[1–3], mainly by annealing with the 39 UTR
of the target mRNA, thus interfering with its translation and/or
stability[4]. MiRNAs play important roles in the regulation of
basic cell functions, including proliferation, differentiation and
apoptosis[5–8]. Importantly, oncogenesis has been linked to
deregulated expression of miRNAs, which act as tumor suppres-
sors or oncomirs[9,10] and may contribute to tumor invasion[11].
The miRNA 17-5p-92 cluster comprises seven miRNAs,
transcribed as a polycistronic unit, and is homologous to the
miRNA 106a-92 cluster[12]. We have previously shown that miR-
17-5p,- 20a and -106a regulate monocytopoiesis through AML1
targeting[7]. Growing evidence documents deregulation of the
miRNA 17-5p-92 cluster in cancer. Specifically, a genomic region
containing the miRNA 17-5p-92 polycistron is amplified in B-cell
lymphomas[13]. Furthermore, transcription of miRNA 17-5p-92
cluster is regulated by the oncogene c-myc[14], while its
overexpression can contribute to tumorigenesis[15–18].
Neuroblastoma, accounting for 8–10% of pediatric tumors,
originates from precursor cells of the peripheral nervous system.
The most aggressive neuroblastomas are characterized by diverse
genetic aberrations, including MYCN amplification, chromosome
1p deletion and unbalanced gain of chromosome 17q[19]. MYCN
amplification occurs in 25% of the cases and correlates to both an
aggressive phenotype and treatment failure[19]. The neuroblasto-
ma progression linked to MYCN amplification, although well
documented, is mediated by unknown molecular mechanisms.
Some miRNAs, including miR-9, miR-125 and miR-34a control
neuroblastoma cell proliferation in vitro[20,21], but their function
hasnot been linkedtoneuroblastoma carryingMYCN amplification.
p21
Cip1/Waf1/Sdi1 (hereafter referred to as p21), the founding
member of the Cip/Kip family of cyclin-dependent kinase (CDK)
inhibitors, negatively regulates cell cycle progression by inhibiting a
broad range of cyclin/Cdk complexes[22]. Specifically, p21
prevents cell cycle progression from G1 to S phase by inactivating
the Cdk2-cyclin E complexes, that, in turn, inhibit the tumor
suppressor protein retinoblastoma (pRb) required for entering S-
phase[23]. It can also act as a tumor suppressor, as demonstrated by
the higher susceptibility of p21-deficient mice to develop spontane-
ous tumors[24]. In spite of this, genetic alterations of p21 are rare in
human tumor samples[25], suggesting that its oncogenic function is
mostly mediated by a deregulated expression.
BIM (Bcl-2 interacting mediator of cell death) is one of the most
potent pro-apoptotic BH3-only proteins: it binds to all pro-survival
Bcl-2 family members with high affinity[26,27], thereby releasing
Bax or Bak proteins, the critical downstream effectors of the Bcl-2-
dependent pathway of apoptosis[28]. BIM is a tumor suppressor
PLoS ONE | www.plosone.org 1 May 2008 | Volume 3 | Issue 5 | e2236gene, as demonstrated by the accelerated Myc-induced lympho-
magenesis in Em-myc mice lacking BIM[29] and increased
tumorigenesis of BIM-/- epithelial cells[30] .
In this study, we have investigated the molecular mechanisms
underlying MYCN-induced neuroblastoma progression. Our
findings indicate that an enhanced MYCN level, linked or not
to MYCN amplification, transactivates the miRNA 17-5p-92
cluster at transcriptional level. The upmodulation of miR-17-5p
mediates the oncogenic properties of MYCN, through a direct
suppression of p21 and BIM translation. Of particular interest
is that treatment of MYCN-amplified neuroblastoma with antag-
omir-17-5p can abolish tumor growth, not only in vitro but also
in vivo.
Results
MYCN transcriptionally regulates the expression of
miRNA 17-5p-92 cluster in neuroblastoma
Transcription of the miRNA 17-5p-92 cluster is induced by the
oncogene c-Myc[14]. Since c-Myc and MYCN share some
transcriptional target, we hypothesized that MYCN may trans-
activate this cluster.
To verify this hypothesis, we first analyzed the expression of the
miRNA 17-5p-92 cluster in five neuroblastoma cell lines
expressing MYCN at either low level (SH-EP and SK-N-AS) or
high level due to MYCN overexpression (SH-SY-5Y) or amplifi-
cation (LAN-5 and IMR32) (Figure 1A). Most miRNAs encoded
by the miRNA 17-5p-92 cluster were expressed at higher levels in
cells overexpressing MYCN or carrying MYCN amplification, as
evaluated by both Northern blot and qRT-PCR (Figure 1B and
data not shown).
Thereafter, analysis of the genomic region surrounding the
miRNA 17-5p-92 cluster for putative MYCN binding sites
(including the canonical E-box CACGTG and the non-canonical
sequences CATGTG, CACGGG and CAAGTG) revealed the
presence of five MYCN putative binding sites, four upstream and
one downstream the cluster (Figure 1C). To demonstrate the
interaction between MYCN and the cluster promoter, chromatin
immunoprecipitation (ChIP) experiments were performed using
the Tet-21/N cell line, which expresses MYCN under a
tetracycline- regulated promoter[31]. DNA immunoprecipitated
with an anti-MYCN antibody from untreated or doxycycline-
treated (for 2 or 24 h) cells was PCR-amplified using five different
pairs of oligonucleotide primers encompassing the five putative
MYCN-binding sites (Figure 1C). MYCN was associated with all
the putative binding sites; furthermore, the signal decreased in
parallel with MYCN downmodulation by doxycycline treatment.
These results demonstrate the in vivo binding of MYCN with all
these sites (Figure 1D).
Finally, we evaluated the effect of MYCN on miRNA 17-5p-92
cluster expression. A ,3700 bp DNA fragment containing the
four upstream MYCN binding sites was cloned at the 59 site of the
luciferase gene in the reporter pGL4 vector (pGL4prom17M)
(Figure 1C). Co-transfection of this construct together with an
expression vector for MYCN in SH-EP cells led to a sharp
transactivation of the luciferase activity, which was not detected in
the control empty vector group (Figure 1E). Moreover, in Tet-21/
N cells downmodulation of MYCN by doxycycline treatment
caused a marked decrease of all miRNAs encoded by the miRNA
17-5p-92 cluster, as evaluated by both Northern blot and qRT-
PCR (Figure 1F and data not shown).
Altogether these results indicate that, in neuroblastoma cells,
MYCN transcriptionally induces the expression of the miRNA 17-
5p-92 cluster by directly binding to its promoter.
miRNA 17-5p-92 cluster enhances the in vitro and in vivo
tumorigenesis of SK-N-AS neuroblastoma cell line
In order to investigate the oncogenic role of the miRNA 17-5p-
92 cluster in neuroblastoma, we generated a stable SK-N-AS
transfectant expressing the cluster under a CMV promoter (SK-N-
AS 17-5p cluster). These cells showed an increased expression of
the cluster (data not shown), similar to that observed in MYCN-
amplified neuroblastoma cells (Figure 1B).
In a series of in vitro experiments, ectopic expression of the
cluster induced: (i) an increase of the proliferation rate , as
compared to control cells stably transfected with an empty vector
(SK-N-AS Cont) (Figure 2A, B); (ii) a decline of the percentage of
cells in G1 phase and an inverse rise of the S phase population,
demonstrating an accelerated cell cycle progression (Figure 2C);
(iii) an increase of the number of colonies formed in a soft-agar
semisolid medium, demonstrating a rise of the tumorigenic ability
(Figure 2D).
To evaluate the effect of the cluster on in vivo tumorigenesis, we
injected SK-N-AS Cont or SK-N-AS 17-5p cluster cells into nude
mice. All mice (11/11) injected with SK-N-AS 17-5p cluster cells
developed a tumor and died within 130 days from injection,
whereas only 36% of mice (4/11) injected with SK-N-AS Cont
cells showed a visible tumor (Figure 2E).
Altogether, these data demonstrate that the miRNA 17-5p-92
cluster enhances cell proliferation and promotes tumorigenesis,
both in vitro and in vivo.
miR-17-5p is responsible for the tumorigenic effect of the
miRNA 17-5p-92 cluster through direct downmodulation
of p21
To identify potential target genes of the miRNAs encoded by
the miRNA 17-5p-92 cluster, we used two algorithms, Target
Scan[32] and PicTar[33]. Both indicated that p21 is a candidate
target of miR-17-5p and -20a. Since miR-17-5p and -20a share
similar sequences and functions[7,14], we focused on miR-17-5p
for further analysis of p21 targeting.
We first evaluated the expression of p21 in Tet-21/N cells
treated or not with doxycycline for 96 h. Downmodulation of
MYCN and miR-17-5p caused a strong increase of p21 expression
at both mRNA and protein level (Figures 1F and S1). Consistently,
we observed a clear reduction in the level of endogenous p21
mRNA and protein in SK-N-AS 17-5p cluster cells, as well as in
SK-N-AS transiently transfected with miR-17-5p, but not with
miR-92 (Figure 3A).
To demonstrate that miR-17-5p directly regulates p21 expres-
sion by binding to its 39 UTR, we cloned the p21 39 UTR into the
pGL3-Promoter vector, downstream the luciferase gene (pGL3-
Prom-p21UTR-wt). As a control, we cloned a mutated p21 39
UTR, containing 4 mutations in the miR-17-5p binding site
(pGL3-Prom-p21UTR-mut). Transfection of pGL3-Prom-
p21UTR-wt together with an anti-miR-17-5p oligonucleotide,
but not with either a scrambled anti-miR-17-5p or an anti-miR-92,
led to an increase of the luciferase activity in Tet-21/N cells, due
to inhibition of the endogenous miR-17-5p. Conversely, the anti-
miR-17-5p oligonucleotide did not increase the luciferase activity
of pGL3-Prom-p21UTR-mut, thus demonstrating that mutation
of the miR-17-5p binding site in the p21 39 UTR abolished the
ability of miR-17-5p to regulate its expression (Figure 4B).
Transfection of anti-miR-20a enhanced the luciferase activity of
PGL3-Prom-p21UTR-wt, as observed for anti-miR-17-5p, thus
suggesting that miR-20a also targets p21 mRNA (data not shown).
SK-N-AS transfected with miR-17-5p showed a higher
percentage of cells in the S phase and a lower number of cells in
Antagomir-17-5p Neuroblastoma
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92 did not affect cell cycle progression (Figures 2C and 3C). Since
regulation of p21 expression by miRNA 17-5p-92 cluster is
essentially mediated by miR-17-5p, we hypothesized that the
effects of the cluster on the in vitro tumorigenesis of SK-N-AS cells
were also mediated by miR-17-5p. In fact, overexpression of miR-
17-5p, but not of miR-92, increased the number of colonies
formed by SK-N-AS in a semisolid medium, as observed for cells
Figure 1. MYCN transactivates the miRNA 17-5p-92 cluster in neuroblastoma by directly binding to its promoter. (A) Western blot of
MYCN in different neuroblastoma cell lines. A representative experiment is shown. (B) miRNA qRT-PCR analysis of miRNAs pertaining to the miRNA
17-5p-92 cluster in different neuroblastoma cell lines. The level of each miRNA is normalized to its expression in SK-N-AS cells (set as 1). Mean6s.d.
(n=3). (C) Schematic representation of the genomic region encompassing the miRNA 17-5p-92 cluster. Five putative MYCN binding sites (included in
fragments 1, 2, 3, 4, 5) are indicated. (D) Left panel. Representative Western blot of MYCN in Tet-21/N cells untreated (0 h) or treated with doxycycline
(Dox) for 2 or 24 h. ERp57 was used for normalization. Right panel. Chromatin immunoprecipitation with an anti-MYCN or a control anti-IgG
antibodies on lysates from Tet-21/N cells untreated or treated with doxycycline for the indicated times. Control amplifications were carried out on
either chromatin before immunoprecipitation (Input) or immunoprecipitated chromatin with oligonucleotides amplifying the b-actin gene (Actin). (E)
Promoter assay with the pGL4Prom17M construct containing a 3731 bp fragment of the miRNA 17-5p-92 cluster promoter upstream the luciferase
gene (indicated in C). SH-EP cells were transfected with pGL4 vector (Empty) or pGL4Prom17M (Prom17M) in combination with pcDNA3 (pcDNA) or
piRV-neoSV-MYCN and luciferase activity was measured 72 h post-transfection. The bars represent the normalized luciferase activity (mean6s.d.,
n=5). (F) miRNA qRT-PCR analysis of miRNAs pertaining to the miRNA 17-5p-92 cluster in Tet-21/N untreated (2 Dox) or treated with doxycycline for
96 h (+ Dox). The level of each miRNA is reported as percentage of its expression in untreated cells (set as 100%). Mean6s.d. (n=3). * P,0.05,
** P,0.01, *** P,0.001.
doi:10.1371/journal.pone.0002236.g001
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these results show that miR-17-5p is the major effector of MYCN-
mediated in vitro tumorigenesis of SK-N-AS cells.
The role of p21 in the control of cell cycle progression and
tumorigenesis of SK-N-AS cells was demonstrated by knocking
down p21 with siRNA. Notably, silencing of p21 was associated
with an accelerated cell cycle progression, as well as an increased
ability of these cells to form colonies in a semisolid medium, as
observed upon overexpression of either the miRNA 17-5p-92
cluster or miR-17-5p (Figure 3E and data not shown). Importantly,
restoration of p21 in SK-N-AS 17-5p cluster cells abolished the in
vitro tumorigenic activity of these cells by blocking miRNA 17-5p-
92 cluster-induced cell cycle acceleration (Figure 3F, G). Finally,
overexpression of miR-17-5p in SH-EP cells (a MYCN-not-
amplified neuroblastoma cell line) enhanced cell proliferation
through downmodulation of p21, as observed in SK-N-AS cells,
thus demonstrating that these effects were not restricted to a
particular cell line (data not shown).
Altogether, these results show that downregulation of p21
mediates miR-17-5p induced tumorigenesis in neuroblastoma cell
lines.
Knockdown of miR-17-5p decreases the in vitro
tumorigenesis of MYCN-amplified neuroblastoma cells
To determine whether miR-17-5p mediates tumorigenesis in
MYCN-amplified neuroblastoma cells, we evaluated the effect of
miR-17-5p knockdown in LAN-5 cell line, which expresses miR-
17-5p at elevated level (Figure 1B). In preliminary experiments,
treatment of LAN-5 with antagomir-17-5p (a chemically modified
anti-miR-17-5p oligonucleotide conjugated with cholesterol[34])
efficiently downmodulated miR-17-5p expression, as compared to
cells treated with PBS or control antagomir-1 (data not shown).
Incubation of LAN-5 with antagomir-17-5p, but not with the
control antagomir, markedly inhibited cell proliferation, decreased
in vitro tumorigenesis in soft agar and blocked cell cycle progression
(Figure 4A, B and data not shown). Furthermore, inhibition of
miR-17-5p was associated with an increase of p21 mRNA and
protein level (Figure 4C).
In addition, knockdown of miR-17-5p strongly promoted both
early and late apoptosis (Figure 4D). Notably, p21 overexpression
did not induce apoptosis in LAN-5 (data not shown), thus implying
that an additional miR-17-5p target may regulate this process.
Bioinformatic analysis with Target Scan[32], Pic Tar[33] and
Figure 2. Overexpression of miRNA 17-5p-92 cluster augments in vitro and in vivo tumorigenesis of SK-N-AS cells. (A) Proliferation
curve of SK-N-AS stably transfected with the empty vector (Cont) or the vector expressing the miRNA 17-5p-92 cluster (17-5p cluster). Mean6s.d.
(n=3). (B) Thymidine incorporation in SK-N-AS Cont or 17-5p cluster cells. Mean6s.d. (n=3). (C) Cell cycle analysis of SK-N-AS Cont or 17-5p cluster
cells. After 30 h starvation, cells were incubated with a complete medium for 16 h before BrdU incorporation and FACS analysis. Percentage of cells in
G1, S or G2-M phase of the cell cycle is indicated. A representative experiment is shown. (D) Anchorage independent growth of SK-N-AS Cont or 17-
5p cluster cells. Cells were plated in a soft agar semisolid medium and colonies were counted after 2 weeks. In each experiment, cells were plated in
triplicate. Representative fields are shown. Numbers indicate the fold increase of the colony number formed by SK-N-AS 17-5p cluster cells relative to
SK-N-AS Cont cells (set as 1). Mean6s.d. (n=5); P,0.001. (E) Left panel. Nude mice were injected with SK-N-AS Cont or 17-5p cluster cells and
photographed four months after the injection. Representative mice are shown. Right panel. Kaplan-Meier curves showing survival of mice injected
with SK-N-AS Cont (grey line) or 17-5p cluster cells (black line); P,0.05 (n=11). ** P,0.01, *** P,0.001.
doi:10.1371/journal.pone.0002236.g002
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target of miR-17-5p. Consistently, knockdown of miR-17-5p by
antagomir increased BIM expression at both mRNA and protein
level in LAN-5 cells (Figure 4E). To demonstrate that this
regulation occurs through a direct binding of miR-17-5p to BIM 39
UTR, we cloned a portion of the BIM 39 UTR containing the
miR-17-5p putative binding site into the pGL3-Promoter vector,
downstream the luciferase gene (pGL3-Prom-BIMUTR-wt). As a
control, we cloned a region of BIM 39 UTR containing a mutated
miR-17-5p recognition site (pGL3-Cont-BIM UTR-mut). Co-
transfection of pGL3-Prom-BIMUTR-wt together with an anti
miR-17-5p, but not with a scrambled anti-miR-17-5p oligonucle-
Figure 3. miR-17-5p mediates the oncogenic function of miRNA 17-5p-92 cluster through p21 and cell cycle regulation. (A) Western
blot (left panel) and qRT-PCR (right panel) of p21 expression in SK-N-AS Cont or 17-5p cluster cells, or in SK-N-AS transiently transfected with miR-17-
5p,- 92 or a control miRNA. A representative Western blot is shown. Mean6s.d. (n=3). (B) Luciferase activity in Tet-21/N cells transfected with pGL3-
prom-p21UTR wt or mut in combination with a control or anti-miRNA oligonucleotides complementary to miR-17-5p or -92. The ratio of normalized
luciferase activity in pGL3-prom-p21UTR wt versus mut transfected cells is indicated. Mean6s.d. (n=6). (C) Cell cycle analysis of SK-N-AS cells
transfected with miR-17-5p,- 92 or a control miRNA. After transfection, cells were starved for 30 h and then incubated with a complete medium for
16 h before BrdU incorporation and FACS analysis. Percentage of cells in G1, S or G2-M phase of the cell cycle is indicated. A representative
experiment is shown. (D) Anchorage independent growth of SK-N-AS cells transfected with miRNA-17-5p,- 92 or a control miRNA. Cells were plated in
a soft agar semisolid medium and colonies were counted after 2 weeks. In each experiment, cells were plated in triplicate. A representative field is
shown. Numbers indicate the fold increase of the colony number formed by SK-N-AS transfected with miR-17-5p or -92 relative to SK-N-AS cells
transfected with a control miRNA (set as 1). Mean6s.d. (n=3); P,0.001. (E) Colony formation of SK-N-AS cells transfected with siRNA targeting p21
mRNA (p21 siRNA) or a control oligonucleotide (Cont siRNA). After transfection, cells were plated in a soft agar semisolid medium and colonies were
counted after 2 weeks. In each experiment, cells were plated in triplicate. A representative field is shown. Numbers indicate the fold increase of the
colony number formed by SK-N-AS transfected with p21 siRNA relative to SK-N-AS cells transfected with a control siRNA (set as 1). Mean6s.d. (n=3);
P,0.001. (F) Colony formation of SK-N-AS 17-5p cluster cells stably transfected with an expression vector for p21 or the empty plasmid (pcDNA). Cells
were plated in a soft agar semisolid medium and colonies were counted after 2 weeks. In each experiment, cells were plated in triplicate. A
representative field is shown. Numbers indicate the fold increase of the colony number formed by SK-N-AS 17-5p cluster cells transfected with an
expression vector for p21 relative to cells transfected with the empty plasmid (set as 1). Mean6s.d. (n=3); P,0.001. (G) Cell cycle analysis of SK-N-AS
17-5p cluster cells stably transfected with an expression vector for p21 or the empty plasmid (pcDNA). Cells were starved for 24 h and then incubated
with a complete medium for 16 h before BrdU incorporation and FACS analysis. Percentage of cells in G1, S or G2-M phase of the cell cycle is
indicated. A representative experiment is shown. *** P,0.001.
doi:10.1371/journal.pone.0002236.g003
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cells (Figure 4F). This increase was not observed in cells transfected
with the pGL3-Cont-BIM UTR-mut construct, thus demonstrat-
ing that mutation of the miR-17-5p binding site in the BIM 39
UTR abolishes the ability of miR-17-5p to regulate its expression
(Figure 4F).
Knockdown of miR-17-5p inhibits the in vivo tumorigenic
ability of MYCN-amplified neuroblastoma cells
Based on the in vitro studies, we hypothesized that abolition of
miR-17-5p expression may inhibit tumor growth in vivo.T o
address this critical question, MYCN-amplified LAN-5 cells were
injected into nude mice, and tumors thereby generated were
treated with antagomir-17-5p or a control antagomir for two
weeks. Injection of antagomir-17-5p dramatically inhibited tumor
growth: this effect , already relevant after one week of therapy was
maintained through the end of the treatment, leading in 30% of
cases to complete regression of the tumor mass (Figure 5A, B).
Conversely, administration of the control antagomir did not affect
tumor development, as observed in PBS-treated tumors (data not
shown). Tumor analysis at 24 h after the first administration of
antagomir-17-5p showed a marked downmodulation of miR-17-
5p, associated with a strong increase of p21 and BIM at both
mRNA and protein level (Figure 5C, D and data not shown).
Consistently, TUNEL assay showed an increased apoptosis in
tumors treated with antagomir-17-5p, as compared to the control
group (Figure 5C, D).
Altogether, these results demonstrate that in vivo treatment of
MYCN-amplified neuroblastoma with antagomir-17-5p abolishes
tumor growth by upmodulation of p21 and BIM and increased
apoptosis.
Figure 4. Treatment of MYCN-amplified LAN-5 cells with antagomir-17-5p inhibits in vitro tumorigenesis through p21 and BIM
upmodulation. (A) Colony formation of LAN-5 cells treated with antagomir-17-5p or a control antagomir. 24 h after treatment, cells were plated in
a soft agar semisolid medium and colonies were counted after 2 weeks. In each experiment, cells were plated in triplicate. Mean6s.d. (n=3). (B) Cell
cycle analysis of LAN-5 cells treated with antagomir-17-5p or a control antagomir. After treatment, cells were starved for 24 h and then incubated
with a complete medium for 16 h before BrdU incorporation and FACS analysis. Percentage of cells in G1, S or G2-M phase of the cell cycle is
indicated. A representative experiment is shown. (C) Western blot (left panel) and qRT-PCR (right panel) of p21 expression in LAN-5 cells treated with
antagomir-17-5p or a control antagomir. A representative Western blot is shown. Mean6s.d. (n=3). (D) Apoptosis of LAN-5 cells treated with
antagomir-17-5p or a control antagomir. 24 h after treatment, cells were incubated with Annexin V and Cytox Green and analyzed by FACS. A
representative experiment is shown. (E) Western blot (left panel) and qRT-PCR (right panel) of BIM expression in LAN-5 cells treated with antagomir-
17-5p or a control antagomir. A representative Western blot is shown. Mean6s.d. (n=3). (F) Luciferase activity in Tet-21/N cells transfected with pGL3-
prom-BIMUTR wt or mut in combination with a control or an anti-miRNA oligonucleotide complementary to miR-17-5p. The ratio of normalized
luciferase activity in pGL3-prom-BIMUTR wt versus mut transfected cells is indicated. Mean6s.d. (n=6). * P,0.05, ** P,0.01, *** P,0.001.
doi:10.1371/journal.pone.0002236.g004
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neuroblastoma samples
Finally, we evaluated the expression of MYCN,m i R - 17-5p and
p21 mRNA in freshly dissected primary neuroblastomas, including
MYCN-amplified and not-amplified tumors (Figure 6). In MYCN-
amplified tumors the upmodulation of MYCN was associated with
elevated miR-17-5p expression and markedly low levels of p21
(group1).MYCN-not-amplified neuroblastomas,showinga lowlevel
of MYCN, displayed two distinct patterns: (i) 30% of cases were
characterized by low miR-17-5p expression and high-level of p21
(group 2); (ii) 70% of samples unexpectedly showed an elevated
expression of miR-17-5p, associated with moderate downmodula-
tion of p21 (group 3), less pronounced than in group 1.
Figure 5. Treatment of MYCN-amplified LAN5 cells with antagomir-17-5p inhibits in vivo tumorigenesis through p21 and BIM
upmodulation. (A) Nude mice were injected with MYCN-amplified LAN-5 cells and treated when tumors reached 150 mm
3 with antagomir-17-5p or
a control antagomir for 2 weeks. Representative mice were photographed four weeks after the first injection. (B) Growth curves of LAN-5 tumors
treated with antagomir-17-5p or a control antagomir for 2 weeks (injections of antagomirs are indicated by arrows). The volume of the tumors was
measured three times weekly and is plotted as the fold increase relative to the day of the first antagomir injection (day 0), set as 1. Mean6s.e.m.
(n=11for cont; n=10for Antagomir-17-5p). (C) Immunohistochemistry on LAN-5 tumors treated with antagomir-17-5p or a control antagomir for
24 h. Sections derived from tumors were incubated with an anti-p21 antibody (upper panels), an anti-BIM antibody (middle panels) or with TUNEL for
detection of apoptotic cells (lower panels). Representative fields are shown. (D) qRT-PCR of p21 (upper panel)o rBIM (middle panel) mRNA levels in
tumors formed by LAN-5 cells and treated with antagomir-17-5p or a control antagomir for 24 h. Mean6s.d. (n=3). Lower panel. TUNEL positive cells
in tumors treated with antagomir-17-5p or a control antagomir for 24 h. Mean6s.e.m. (n=16). ** P,0.01, *** P,0.001.
doi:10.1371/journal.pone.0002236.g005
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Neuroblastoma is one of the most common extra-cranial solid
tumor of early childhood, accounting for .15% of cancer-related
deaths in children. While the clinical diversity of neuroblastoma
correlates with several genetic features, such as ploidy or allelic
loss, the amplification of the MYCN gene is the best genetic marker
of poor prognosis[36]. However, the mechanisms underlying
MYCN-mediated neuroblastoma progression have not been
identified. Our work describes a novel oncogenic pathway
underlying neuroblastoma development, whereby MYCN trans-
activates the miRNA 17-5p-92 cluster, which in turn down-
modulates the tumor suppressors p21 and BIM. Among the
different miRNAs pertaining to the miRNA 17-5p-92 cluster,
miR-17-5p and miR-20a, which show an almost complete
homology, are the only ones targeting p21, as indicated by
bioinformatic analysis and luciferase assay. Furthermore, miR-17-
5p level in neuroblastoma cell lines is often more elevated than that
of miR-20a. Therefore, we focused on miR-17-5p as the primary
effector of MYCN-mediated tumorigenesis.
Our studies indicate that, in neuroblastoma cell lines, miR-17-5p
controls cell cycle progression through p21. In diverse tumors miR-
106b, structurally related to but functionally distinct from miR-17-
5p[7], regulates cell cycle progression through p21[37]. However,
we observed that miR-106b is not upmodulated in MYCN-amplified
neuroblastoma cells (data not shown), thus suggesting that in
neuroblastoma miR-106b is not involved in p21 regulation.
p21 is a tumor suppressor gene, whose expression is mainly
regulated at transcriptional level by p53[38]. Although p53 is the
most frequently mutated gene in human cancers, p53 mutations
have not been detected in primary neuroblastoma[39]. In
addition, lack of correlation between p53 and p21 levels in
MYCN-amplified neuroblastoma cell lines[40] suggests that
expression of p21 may be p53-independent in neuroblastoma.
Our study shows a novel p53-independent mechanism for the
regulation of p21 expression. In fact, we report that miR-17-5p
Figure 6. miR-17-5p expression is correlated to MYCN and p21 levels in human primary neuroblastomas. (A) Expression of MYCN, miR-
17-5p and p21 was analyzed in primary tumors by qRT-PCR. Depending on the expression levels of MYCN and miR-17-5p, primary tumors were divided
into three groups. Group 1 (left upper panel) includes MYCN-amplified tumors displaying high levels of miR-17-5p and very low levels of p21. Group 2
(right upper panel) includes MYCN-not-amplified tumors expressing low levels of miR-17-5p and high levels of p21. Group 3 (lower panel) includes
MYCN-not-amplified tumors expressing high levels of miR-17-5p and moderately low levels of p21 (a 40% decrease baseline is shown). The coloured
boxes indicate the tumor stage (from I to IV) and the therapy resistant tumors (TR). (B) Expression of MYCN, miR-17-5p and p21 in the three groups of
primary tumors. Mean6s.d.. ** P,0.01, *** P,0.001 when compared to second group; uuu P,0.001 when compared to the other groups.
doi:10.1371/journal.pone.0002236.g006
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and the SH-EP and LAN-5 cells expressing endogenous p53[41].
Furthermore, treatment of LAN-5 with antagomir-17-5p caused an
upmodulation of p21 without affecting p53 levels (data not shown).
Id2 has also been proposed to mediate MYCN ability to bypass the
cell cycle checkpoint imposed by Rb[42]. However, a direct binding
of MYCN to Id2 promoter has not been demonstrated and Id2
expression does not seem to be associated with MYCN amplifica-
tion or expression in human neuroblastoma[43].
Treatment of LAN-5 with antagomir-17-5p causes not only a
block of cell cycle, but also a dramatic apoptosis. Tumor
progression usually occurs through activation of different path-
ways, leading to increased cell proliferation and protection from
apoptosis, which provides a survival advantage to cancer cells.
Oncoproteins of the myc family promote apoptosis[44–46].
However, MYCN amplification in neuroblastoma causes resistance
to chemotherapy, associated with tumor progression and poor
prognosis[36]: this suggests that MYCN-induced apoptosis may be
inhibited by an additional oncogenic mechanism, crucial for
tumor progression. Our findings indicate that miR-17-5p is a key
factor inducing protection from MYCN-primed apoptosis in
neuroblastoma. Indeed, knock down of miR-17-5p is sufficient to
promote massive apoptosis of MYCN-amplified LAN-5 cells. This
occurs through upmodulation of the proapoptotic factor BIM,
mediated by direct binding of miR-17-5p to BIM mRNA 39 UTR.
The ‘‘combinatorial circuitry model’’, predicts that a single
miRNA may target multiple mRNAs. In MYCN-amplified
neuroblastoma MYCN transactivates miR-17-5p, which in turn
accelerates cell cycle progression by downmodulating p21 and
protects cells from apoptosis by inhibiting BIM expression
(Figure 7). This occurs in a p53-independent manner, thus
providing a mechanistic explanation for the rarity of p53
mutations in neuroblastoma.
A second set of studies was focused on the molecular analysis of
primary neuroblastoma samples, derived from a well characterized
series of patients. The samples were divided in three groups. The
first and second ones yielded expected results. Specifically, the first
group is characterized by MYCN-amplification, poor prognosis and
therapy resistance, coupled with a marked rise of miR-17-5p level
and a dramatic decrease of p21. The second one features low levels of
MYCN and miR-17-5p, associated with elevated p21 expression:
these patients show a relatively benign clinical profile, character-
ized by slow disease progression and therapy response. Surpris-
ingly, the third, large group of samples shows an elevated level of miR-
17-5p in the absence of increased MYCN expression. The levels of
p21 are intermediate between those of the first and the second
groups, while the clinical features are relatively benign. In line with
these clinical observations, we observed that, in neuroblastoma cell
lines with normal MYCN level, overexpression of miRNA 17-5p-
92 cluster, as well as miR-17-5p alone, is able to enhance
Figure 7. Mechanism of antagomir-17-5p action in the treatment of MYCN-amplified neuroblastoma. In MYCN-amplified neuroblatoma,
MYCN binds the miRNA 17-5p-92 cluster promoter and transactivates the miR-17-5p. High levels of miR-17-5p inhibit the translation of p21 and BIM
through the direct binding to their mRNA 39 UTRs. Low levels of p21 and BIM lead to an accelerated cell cycle progression and a resistance to
apoptosis, respectively. Treatment of MYCN-amplified cells with antagomir-17-5p inhibits miR-17-5p function, thus allowing the translation of both
p21 and BIM mRNA. High levels of p21 and BIM cause a block of cell cycle and induction of apoptosis, respectively, thus inhibiting tumor growth.
doi:10.1371/journal.pone.0002236.g007
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require MYCN to exert its oncogenic activity in neuroblastoma.
Notably, knock down of miR-17-5p by antagomir sharply inhibits
the in vitro and in vivo tumorigenesis of MYCN-amplified LAN-5
cells, suggesting that miR-17-5p is a key oncogenic factor in both
MYCN-amplified and not-amplified neuroblastoma.
The lower level of p21 observed in the first group, as compared
to the third one, may be due to a direct downmodulation of p21 by
MYCN. In fact, c-Myc negatively regulates the expression of p21
at transcriptional level[47]. Preliminary results indicate that
MYCN binds the p21 promoter, suggesting that in MYCN-
amplified neuroblastoma MYCN exerts an additional suppressing
activity on p21 expression at transcriptional level (data not shown).
In the clinical setting, the remarkably low level of p21 in the
second group is probably linked to its poor prognosis and therapy
resistance.
Our antagomir studies bear a potential significance at clinical
level. Despite recent advances in treatment options, aggressive
neuroblastoma carrying MYCN amplification is refractory to
current therapy, leading to a disease related mortality of up to
70%. Therefore, the development of new therapeutic approaches
is warranted. Strategies based on MYCN repression by siRNA may
prove unsatisfactory: in fact, efficient inhibition of MYCN levels is
hampered by the high levels of MYCN. Conversely, antagomir-
17-5p treatment may be beneficial in MYCN-amplified neuroblas-
toma, also in view of evidence suggesting that systemic antagomir
treatment is not coupled with significant toxicity[34,48]. In
conclusion, our results provide the first demonstration that
antagomirs can efficiently inhibit tumor growth in vivo, thus raising
the possibility that these molecules may ultimately be clinically
useful in the treatment of cancer.
Materials and Methods
Cell culture and tumor samples
The SH-EP and SK-N-AS human neuroblastoma cell lines
express low levels of MYCN whereas SH-SY-5Y, LAN-5 and
IMR32 overexpress MYCN (LAN-5 and IMR32 as a result of
gene amplification). All the cells, obtained from the American
Type Culture Collection, (Manassas, VA), were grown in RPMI
medium supplemented with 10% FBS (HyClone, Logan, Utah).
Tumor samples were obtained from patients diagnosed with
neuroblastoma after informed consent of their parents admitted to
the Division of Oncology at Bambino Gesu ` Children’s Hospital.
Samples were freshly resected during surgery and immediately
frozen in liquid nitrogen for subsequent total RNA extraction.
Tumors were classified according to the International Neuroblas-
toma Pathology Classification (INCP): 6 were at stage I, 2 at stage
II, 1 at stage III, and 8 at stage IV.
For proliferation assay, cells were seeded at the same density
(2.5610
4 cells/ml) and counted at the indicated times. For
thymidine incorporation assay, 50610
3 cells/well were plated in
96 well plates in triplicated; 24 h after seeding, each well was
incubated with 1 mCi of [
3H] thymidine (Amersham Biosciences).
After 16 h, the cells were harvested and analysed by liquid
scintillation in a Microcounter (Wallac). The counts from triplicate
wells were averages.
The in vitro tumorigenesis of neuroblastoma cell lines was
determined by seeding the cells at low density (400–600 cells/ml)
in 1.5 ml of 0.3% Agar Noble (Difco, Kansas City, Missouri) and
RPMI-10% FBS and plating them on 1.5 ml of 0.6% Agar Noble
and RPMI-10% FBS. Colony formation was determined after two
weeks by staining with crystal violet (Fluka, St. Gallen,
Switzerland) and colonies were counted visually.
SK-N-AS Cont and SK-N-AS 17-5p cluster cells were obtained
by transfection of the SK-N-AS cells with the empty vector or the
miRNA 17-5p-92 cluster expression constructs, followed by two
weeks of blasticidin selection at 0.5 mg/ml. SK-N-AS 17-5p cluster
cells stably expressing the p21 expression vector or the empty
pcDNA3, were obtained by two weeks of hygromicin selection at
100 mg/ml, after transfection with Lipofectamine 2000 (Invitro-
gen, Carlsbad, CA).
Oligonucleotides and transfection experiments
For transfection experiments, cells were seeded in antibiotic-free
media for 24 h and then transfected with Lipofectamine 2000
according to manufacturer’s instructions (Invitrogen). Transfection
of a pool of four siRNA oligonucleotides specifically targeting p21
(Smart Pool siRNA, Dharmacon, Lafayette, CO), at the final
concentration of 10 nM, was performed with Hiperfect (Qiagen,
Hilden, Germany). When indicated cells were serum starved for
30 h before transfection.
In promoter assays, SH-EP cells were transfected with 0.6 mgo f
firefly luciferase vectors (empty pGL4 or pGL4prom17M vector),
in combination with 1.8 mg of pcDNA3 (Promega corporation,
Madison, WI) or pIRV neo SV-MycN, together with a Renilla
luciferase vector (50 ng) as internal control.
In luciferase experiments, Tet-21/N cells were transfected with
0.4 mg of firefly luciferase vectors (empty pGL3-prom, pGL3-
prom-p21UTR wt or mutant, pGL3-prom-BIM UTR wt or
mutant) and 50 ng of Renilla luciferase vector, together with
160 nM 29-O-Methyl oligonucleotides (anti-17-5p 59-ACUAC-
CUGCACUGUAAGCACUUUG-39; anti-92 59-CAGGCCGG-
GACAAGU GCAAUA-39; anti-control 59-UUCGACGCG-
GAAUACUUCGAU-39; Dharmacon), where indicated. Firefly
luciferase experiments were measured 48 or 72 h after transfection
by using Microlite TLX1 (Dynatech Laboratoires, Chantilly, CA)
and then normalized for Renilla luciferase activity.
Transfection of SK-N-AS was performed with stability
enhanced mature miRNA 17-5p (59-UACCUGCACUGUAAG-
CACUUUGGU-39), 92 (59-GGCCGGGACAAGUGCAAU-
AUG-39) or a control (59-UACUUGCACUAUACUUGUGA-
CAGU-39) double-stranded RNA oligonucleotides (Dharmacon)
at the final concentration of 160 nM.
Cell cycle analysis
Cells were seeded in 6 well plates at 40% of confluence and
incubated at 37uC for 24 h. Cells were then synchronized by
serum depletion for 30 h and pulsed with 10 mM BrdU (Sigma) for
30 min at different times after FCS addition. After BrdU
incorporation, cells were harvested and fixed in ice-cold 70%
ethanol. DNA was denatured with HCl 2N/Triton 20% and
labeled with an anti-BrdU antibody (BD Bioscience) for 1 h. Then,
cells were resuspended in washing buffer and labeled with anti-
mouse APC-conjugated antibody (Beckton Dickinson). Labeled
cells were washed and resuspended in PBS containing 5 mg/ml
propidium iodide and analysed on a FACSCanto flow cytometer
(Beckton Dickinson) using the DIVA software. All the flow
cytometry experiments were performed at least twice and a
representative experiment is shown in each figure.
Tumorigenicity assay in nude mice
Six-week-old nude mice strain C57/BL6 were subcutaneously
injected into the right flank with 25610
6 cells (SKNAS Cont,
SKNAS 17-5p cluster or LAN-5). Tumor size was assessed every
two days by caliper measurement. Tumor volume was calculated
as follow: volume=Dxd
26p/6, where D and d are the longer and
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were sacrificed when tumors reached the volume of 500 mm
3.
In vitro treatment of LAN-5 with antagomir
Antagomirs were synthesized as described[34]. Sequences were
59-ascsuaccugcacuguaagcacusususgs– Chol 39 (antagomir-17-5p),
59-usascauacuucuuuacauuscscsas- Chol 39 (control antagomir-1).
Lower case letters represent 29-O-Methyl-modified oligonucleo-
tides, subscript ‘s’ represents a phosphorothioate linkage, and
‘Chol’ represents linked cholesterol.
LAN-5 cells were seeded in antibiotic-free media at 50–60% of
confluence (6610
5 cells in a six-wells plate) and treated for 24 h
with antagomir-17-5p, control antagomir at a final concentration
of 2.4 mM, or with an equal volume of PBS.Apoptosis was
measured with the Apoptosis Detection Kit (MBL International,
Woburn, MA) according to manufacturer’s instructions. Briefly,
5610
4 cells were stained with Annexin V-Cy5 and Cytox Green
and analyzed using a BD FACSCanto Cytometer.
In vivo administration of antagomir-17-5p in tumors
generated by LAN-5 neuroblastoma cells
25610
6 LAN5 cells were subcutaneuosly injected into the flank
of 6–8-week-old athymic nude mice. After one week, when the
tumors reached an average volume of ,150 mm
3, the tumor-
bearing nude mice were treated with antagomir-17-5p. 100 mlo f
antagomir-17-5p (diluted in PBS at 2 mg/ml), or control
antagomir, or PBS were injected intratumorally three times per
week for two weeks. Tumor diameters were measured at regular
intervals as described above.
DNA constructs
The pGL4prom17M construct was obtained by sequential
cloning into the pGL4.10 vector (Promega) of 3 fragments
amplified by PCR from human genomic DNA. A 1081 base pair
fragment (clone A: nucleotides -3731-2900) was first amplified with
the forward 17-92promAfor (59-ATAGGTACCCCGGAAT-
TTCCTGAACCACAATG-39) and the revers 17-92promArev (59-
GATCTCGAGGGAGTAGCCGCCACCATCTTCGGCT-39)
primers. The obtained DNA was then digested with KpnI and XhoI
and cloned in pGL4.10 vector. A second segment of the cluster
promoter (segment B: nucleotides -2649-1425) was obtained with
the primers: 17-92promBfor 59-GATCTCGAGTCCTGGTGAG-
TCTGCCCGCCCCT-39 and 17-92promBrev 59-GATAGATC-
TAACACCCGAGACTGCAAAGTGCCCG-39 and it was
cloned downstream the fragment A by double digestion with XhoI
and BglII. The last portion of the promoter (fragment C:
nucleotides -1423-1) was obtained by digestion with BglII and
HindIII of the pGL4prom17 construct[7] and cloned upstream of
the luciferase coding sequence.
The p21 39UTR was PCR amplified from human genomic
DNA by using the primers p21 39UTRfor 59-ATAGCTAGCCA-
CAGGAAGCCTGCAGTCCTGG-39 and p21 39UTRrev 59-
CCTGCCCTCGAGAGGTTTACAGTCTAGG-39 and cloned
downstream of the luciferase gene in the pGL3-Cont PLK+
vector[7] by digestion with NheI and XhoI (construct pGL3-Cont-
p21UTR-wt). From this construct the pGL3-Cont-p21UTR-mut
mutant derivative was generated by inverse PCR with the
following primers: p21 inv for 59-AGCAGA AGGGGCCTCACC-
GAGTGGG-39 and p21 inv rev 59-CTGGATCTGTTTACTT-
CTCAAATG-39.
A 1014-nt-long region of the BIM 39UTR was obtained by
PCR with the forward primer BIM 39UTR for (59 ATAGGTACC-
GAAACAGGCCTCATCCCACTTCC-39) and the reverse
primer BIM 39UTR rev (59-ATAGCTAGCGTTCTGGTGC-
CAACAGCCTGGTC-39), containing the KpnI and the NheI
restriction sites, respectively, and cloned downstream of the
luciferase stop codon in the pGL3-Cont PLK+ vector. The
mutant derivative of this construct (construct pGL3-Cont-BIM
UTR-mut) was generated by inverse PCR with the following
primers: BIM inv for 59-CCTGTAGA GACTCTGTTTCCT-
CAGCCCTG-39 and BIM inv rev 59-TTGAGTCTCACTGG-
CACGTGAGTA CAGGG-39.
The pcDNA6.2-GW/EmGFP-miRNA 17-5p cluster contruct
was obtained by cloning a fragment PCR amplified from human
genomic DNA into pcDNA6.2-GW/EmGFP-miR vector. The
miRNA 17-5p-92 cluster was amplified with the forward primer
17-5p-92cluster-BamH1 (59-GATGGATCCCTAAATGGACCT-
CATATCTTTGAG-39) containing the BamHI site and the
reverse primer 17-5p-92cluster-XhoI (59-GATCTCGAGGAAAA-
CAAGACAAGATGTATTTAC AC-39) containing the XhoI site,
digested with BamHI and XhoI and cloned in pcDNA6.2-GW/
EmGFP-miR vector. pIRV neo SV-MycN and pCEP-WAF1 (p21)
were kindly provided by G Giannini and S. Soddu, respectively.
Northern blot
Total RNA isolation was performed using TRIZOL Reagent
(Invitrogen), following the manufacturer’s instructions. Northern
blot analysis was performed as described[7]. Briefly, RNA samples
(30 mg each) were run on 15% acrylamide urea-denaturing precast
gel (Invitrogen), and transferred onto Hybond-N+ membrane
(Amersham Biosciences, Little Chalfont, UK). The hybridization
was performed overnight with DNA probes previously labelled
with c-32P-ATP, at 37 uC in 0.1% SDS with 66 SSC. Mem-
branes were washed at room temperature twice in 0.1% SDS with
26 SSC. The probes used were: miR-17-5p,5 9-ACTACCTG-
CACTGTAAGCACTTTG-39; miR-18a,5 9-TATCTGCACTA-
GATGCACCTT-39; miR-19a,5 9-TCAGTTTTGCATAGATTT
GCACA-39; miR-19b,5 9-TCAGTTTTGCATGGATTTGC-
ACA-39; miR-20a,5 9-CTACCTGCAC TATGAGCACTTTG-
39; miR-92,5 9-CAGGCCGGGACAAGTGCAATA-39; Met-
tRNA, 59-TGGTAGCAGAGGATGGTTTCGATCCATCGA-
CCTCTG-39.
Real-time RT–PCR
For mRNA analysis, total RNA was purified with TRIZOL
Reagent (Invitrogen). Reverse transcription and Real-time PCR
were performed as described[7]. Expression of mature miRNAs
was determined using miRNA-specific quantitative real-time PCR
(qRT–PCR; Applied Biosystems, Foster City, CA). U6 snRNA
was used for normalization.
Oligonucleotides and transfection experiments
For transfection experiments, cells were seeded in antibiotic-free
media for 24 h and then transfected with Lipofectamine 2000
according to the manufacturer’s instructions (Invitrogen, Carlsbad,
CA). Transfection of a pool of four siRNA oligonucleotides
specifically targeting p21 or BIM mRNAs (Smart Pool siRNA,
Dharmacon) was performed with Hiperfect (Qiagen, Hilden,
Germany).
In promoter assays experiments, SHEP cells were transfected
with 0.6 mg of firefly luciferase vectors (empty pGL4 or
pGL4prom17M vector), in combination with 1.8 mg of pcDNA3
(Promega corporation, Madison, WI) or pIRV neo SV-MycN,
together with a Renilla luciferase vector (50 ng) as internal control.
In luciferase experiments, Tet-21/N cells were transfected with
0.4 mg of firefly luciferase vectors (empty pGL3-prom, pGL3-
prom-p21UTR wt or mutant, pGL3-prom-BIM UTR wt or del)
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Methyl oligonucleotides (anti-17-5p 59-ACUACCUGCACU-
GUAAGCACUUUG-39; anti-92 59-CAGGCCGGGACAAGU-
GCA AUA-39; anti-control 59-UUCGACGCGGAAUACUUC-
GAU-39; Dharmacon, Lafayette, CO), as indicated. Firefly
luciferase experiments were measured 48 or 72 h after transfection
by using Microlite TLX1 (Dynatech Laboratoires, Chantilly, CA)
and then normalized for Renilla luciferase activity.
Transfection of SK-N-AS was performed with stability
enhanced mature miRNA 17-5p (59-UACCUGCACUGUAAG-
CACUUUGGU-39), 92 (59-GGCCGGGACAAGUGCAAU-
AUG-39) or a control (59-UACUUGCACUAUACUUGUGA-
CAGU-39) double-stranded RNA oligonucleotides (Dharmacon)
at the final concentration of 160 nM.
SK-N-AS 17-5p-92 cluster or SKNAS-Cont stable transfectants
were selected by adding 0.5 mg/ml blasticidin to the culture
medium. Stable p21 transfectants in SK-N-AS-17-5p-92 were
obtained by selection in hygromicin (100 mg/ml).
Western blot
Whole cell protein extracts (lysis buffer: 50 mM Tris-HCl
pH 7.5, 150 mM NaCl, 1% NP40, 1 mM PMSF and 16Protease
Inhibitor Cocktail - Sigma-Aldrich, St.Louis, MO) were quantified
by BCA assay (Pierce, Rockford, IL), separated onto NuPAGE
12% polyacrylamide gels (Invitrogen) and blotted on nitrocellulose
membranes (Whatman, England). The filters were hybridized with
polyclonal anti-MYCN, anti-p21, anti-BIM (Santa Cruz Biotech-
nology, CA), followed by a secondary anti-rabbit IgG peroxidase-
conjugated antibody (Biorad, Hercules, CA). The polyclonal
antibody ERp57 and monoclonal antibody anti-actin (Calbio-
chem, Darmstadt, Germany) were used as loading control. Bands
were quantified with Chemi Doc software.
Chromatin immunoprecipitation
Chromatin immunoprecipitation was performed as de-
scribed[49] using an anti-MYCN antibody and amplifying the
immunoprecipitated DNA by PCR with the following oligonucle-
otides derived from the genomic region upstream and downstream
the microRNA 17-5p-92 cluster: fragments 1 forward 59-CAC-
AGCGTACACGTCGAGTC-39 and reverse 59-CCCCACTC-
CCTCATTAGCAT-39; fragments 2 forward 59-CTGGGGGA-
CACAAAGGAG-39 and reverse 59-AACACCCGAGAC TGCA-
AAGT-39; fragments 3 forward 59-TTGCTGTTAGGAGGTTG-
GAAA-39 and reverse 59-CCCATTCCAGAAAACTTCCTT-39;
fragments 4 forward 59-GGAAGCCAGAAGAGGAGGAA-39
and reverse 59-CACTGGAAGTGGTGGCTCTT-39; fragments
5 forward 59-CCAGACTTTGGCAACAGTGA-39 and reverse
59-TTGCCTGTACTTCAGCTTGG-39. Control for non-specif-
ic DNA immunoprecipitation was produced by amplifying a
fragment of the b-actin gene with the following oligonucleotides:
forward 59-CCCTCCAAGAGCTCCTTCTG-39 and reverse 59-
TGTGCTCGCGGGGCGGACGC-39.
Immunohistochemistry
Expression of p21 and BIM was analyzed by immunohisto-
chemistry on 5-mm slices formalin-fixed paraffin-embedded
sections of tumor xenografts by using monoclonal antibody to
p21 (Cell Signaling, Danvers, MA) and polyclonal antibody to
BIM (ProSci Incorporated, Poway, CA). Antigen was retrieved by
pretreating dewaxed sections in a microwave oven at 750 W for
5 minutes in citrate buffer (pH 6) and processing them with a
Super Sensitive Link-Labeled Detection System (Biogenex,
Menarini, Florence, Italy). The enzymatic activity was developed
using 3-amino-9-ethylcarbazole (AEC, Dako, Milan, Italy) as a
chromogenic substrate. Following counterstaining with Mayer’s
haematoxylin, slides were mounted in aqueous mounting medium
(glycergel, Dako).
In situ detection of apoptosis in formalin-fixed, paraffin-
embedded tumor tissues was performed by TUNEL assay
(Apoptag Plus, Chemicon, Prodotti Gianni), as previously
reported[50].
Statistical analysis
Data are presented as mean and error bars indicate the
standard deviation (s.d.) or the standard error (s.e.m.). The groups
were compared by one-way analysis of variance (Anova, Chicago,
IL) using Bonferroni’s test or by the unpaired t-test with two-tailed
p value. Survival data are presented as Kaplan-Meyer plots and
were analysed using a log-rank (Mantel-Haenszel) method.
Significance level was P,0.05.
Supporting Information
Figure S1 p21 is upmodulated in Tet-21/N cells upon treatment
with doxycyclin Western blot (left panel) and qRT-PCR (right
panel) of p21 expression in Tet-21/N untreated or treated with
doxycyclin for 96 h. A representative Western blot is shown.
Mean6s.d. (n=3). *** P,0.001.
Found at: doi:10.1371/journal.pone.0002236.s001 (0.23 MB PPT)
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